Summary
With the exception of the treatment of gout and bacterial infections of joints, therapy in the rheumatic diseases remains inadequate. Although many patients gain symptomatic improvement on the drugs currently available, their impact on the underlying disease process remains uncertain. Hope for future therapeutic development is highest in rheumatoid arthritis with the second-line agents (e.g. gold, penicillamine), as unravelling their mechanism of action may lead to the design of more effective and less toxic medications. The cytotoxic agents appear to hold some promise in the therapy of vasculitis, but problems with their use have by no means been solved.
In the major problem area of Osteoarthritis, important gains are being made in the field of joint replacement, and the use of non-steroidal anti-inflammatory drugs in the interim has made symptoms more tolerable.
Obviously much remains to be done in research in the area of antirheumatic drugs.
Similar content being viewed by others
References
Abel, T.; Urowitz, M.B.; Smythe, H.A.; Keystone, E.C. and Norman, C.S.: Long-term effects of azathioprine in rheumatoid arthritis (abstract). Arthritis and Rheumatism 21: 539 (1978).
Alexander, S. and Brendler, H.: Treatment of uric acid urolithiasis with allopurinol, a xanthine oxidase inhibitor. Journal of Urology 97: 340–343 (1967).
Almeyda, J.; Barnardo, D.; Baker, H.; Levene, C.M. and Landells, J.W.: Structural and functional abnormalities of the liver in psoriasis before and during methotrexate therapy. British Journal of Dermatology 87: 623–631 (1972).
Amatruda, T.T.; Hurat, M.M. and D’Esopo, N.D.: Certain endocrine and metabolic facets of the steroid withdrawal syndrome. Journal of Clinical Endocrinology and Metabolism 25: 1207–1217 (1965).
Ameer, B. and Greenblatt, D.J.: Acetaminophen. Annals of Internal Medicine 87: 202–209 (1977).
Arnett, F.C.; Whelton, J.C.; Zizic, T.M. and Stevens, M.B.: Methotrexate therapy in Polymyositis. Annals of the Rheumatic Diseases 32: 536–546 (1973).
Auerbach, R.: Parenteral vs. oral folic acid antagonists. Archives of Dermatology 90: 553–557 (1964)
Axelrod, L.: Glucocorticoid therapy. Medicine 55: 39–65 (1976).
Ayres, J.W.; Weidler, D.J.; MacKichan, J.; Sakmar, E.; Hallmark, M.R.; Lemanowicz, E.F. and Wagner, J.G. Pharmacokinetics of tolmetin with and without concomitant administration of antacid in man. European Journal of Clinical Pharmacology 12: 421–428 (1977).
Bacon, P.A.; Tribe, C.R.; MacKenzie, J.C.; Verrier Jones, J.; Cumming, R.H. and Amer, B.: Penicillamine nephropathy in rheumatoid arthritis. A clinical, pathological and immunological study. Quarterly Journal of Medicine 45: 661–684 (1976).
Bain, J.S.; El-Ghobarey, A.F.; Collins, R.M. and Sargent, N.W.: Tolmetin: an evaluation of a new preparation in the treatment of rheumatoid arthritis. British Journal of Clinical Practice 29: 208–210 (1975).
Baker, H.: The influence of chloroquin and related drugs on psoriasis and keratoderma blenorrhagicum. British Journal of Dermatology 78: 161–166 (1966).
Balogh, Z.; Papazoglou, S.N.; MacLeod, M. and Buchanan, W.W.: A crossover clinical trial of Piroxicam, indomethacin and ibuprofen in rheumatoid arthritis. Current Medical Research and Opinion 6: 148–153 (1979).
Barker, J.D.; de Carle, D.J. and Auras, S.: Chronic excessive acetaminophen use and liver damage. Annals of Internal Medicine 87: 299–301 (1977).
Barnardo, D.E.; Currey, H.L.F.; Mason, R.M.; Fox, W.R. and Weatherall, M.: Mefenamic acid and flufenamic acid compared with aspirin and Phenylbutazone in rheumatoid arthritis. British Journal of Medicine 2: 342–343 (1966).
Berge, G.; Lundquist, A.; Rorsman, H. and Ackerman, M.: Liver biopsy in psoriasis. British Journal of Dermatology 82: 250–253 (1970).
Bertrand, J.J.; Debeyre, N.; Kahn, M.F. and Ryckewaert, A.: La surveillance oculaire au cours des traitements prolongés par les anti-malariques de synthèse. Presse Medicale 76: 2139–2142 (1968).
Beyer, K.H.; Russo, H.F.; Tillbon, E.K., Miller, A.K.; Verwey, W.F. and Gass, S.R.: “Benemid”, p(di-n-propylsulfamyl) benzoic acid: Its renal affinity and its elimination. American Journal of Physiology 166: 625–640 (1951).
Bird, H.A. and Dixon, A. St.J.: Failure of D-penicillamine to affect peripheral joint involvement in ankylosing Spondylitis or HLA B27 associated arthropathy. Annals of the Rheumatic Diseases 36: 289 (letter) (1977).
Birkhead, N.C.; Wagener, H.P. and Shick, R.M.: Treatment of temporal arteritis with adrenal corticosteroids. Journal of the American Medical Association 163: 821–827 (1957).
Black, R.L.; O’Brien, W.M.; Van Scott, E.J.; Auerbach, R.; Eisen, A.Z. and Bunim, J.J.: Methotrexate therapy in psoriatic arthritis. Double-blind study on 21 patients. Journal of the American Medical Association 189: 743–747 (1964).
Bloch, K.J.; Buchanan, W.W.; Wohl, M.J. and Bunim, J.J.: Sjögren’s syndrome: A clinical, pathological and serological study of sixty-two cases. Medicine 44: 187–231 (1965).
Boardman, P.L. and Hart, F.D.: Side-effects of indomethacin. Annals of the Rheumatic Diseases 26: 127–132 (1967).
Boss, G.R. and Seegmiller, J.E.: Hyperuricemia and gout: Classification, complications and management. New England Journal of Medicine 300: 1459–1467 (1979).
Boston Collaborative Drug Surveillance Program: Excess of ampicillin rashes associated with allopurinol or hyperuricemia. New England Journal of Medicine 286: 505–507 (1972).
Boston Collaborative Drug Surveillance Program: Allopurinol and cytotoxic drugs. Interaction in relation to bone marrow depression. Journal of the American Medical Association 227: 1036–1040 (1974).
Bower, R.J. and Damaino, R.E.: Human tolerability of Sulindac. Abstracts of the XIV International Congress of Rheumatology, San Francisco, p.254 (1977).
Brooks, P.M.; Walker, J.J.: Lee, P.; Bell, A.M.; Buchanan, W.W., Fowler, P.D. and Anderson, JA. Erprobung eines neuen acetylsalicylsaure/paracetamol-praparates mit magensaftresistentem uberzug und zwei verschiedenen dosierungen von Phenylbutazone bei patienten mit primar chronischer polyarthritis anhard eines neuen bewertungsverfahren. Zeitschrift fur Rheumatologie 34: 350–365 (1975).
Brooks, P.M.; Buchanan, W.W.; Grove, M. and Downie, W.W.: Effects of enzyme induction on metabolism of prednisolone. Clinical and laboratory study. Annals of the Rheumatic Diseases 35: 339–343 (1976a).
Brooks, P.M.; Mason, DIR.; McNeil, R.; Anderson, J.A. and Buchanan, W.W.: An assessment of the therapeutic potential of azapropazone in rheumatoid arthritis. Current Medical Research and Opinion 4: 50–56 (1976b).
Bucknall, R.C.; Balint, G. and Dawkins, R.L.: Myasthenia associated with D-penicillamine therapy in rheumatoid arthritis. Scandinavian Journal of Rheumatology Supplement 28: 91–93 (1979).
Bucknall, R.C.; Dixon, A. St.J.; Glick, E.N.; Woodland, J. and Zutshi, D.: Myasthenia gravis associated with penicillamine treatment for rheumatoid arthritis. British Medical Journal 1: 600–602 (1975).
Burns, J.J.; Cucinell, S.A.; Koster, R. and Cowney, A.H.: Application of drug metabolism to drug toxicity studies. Annals of the New York Academy of Sciences 123: 272–286 (1965).
Calabro, J.J.: Sulindac in the treatment of gout: Multicentre studies. European Journal of Rheumatology and Inflammation 1: 21–23 (1978).
Capell, H.A.; Rennie, J.A.N.; Rooney, P.J.; Murdoch, R.M.; Hole, D.J.: Dick, W.C. and Buchanan, W.W.: Patient compliance: A novel method of testing non-steroidal anti-inflammatory analgesics in rheumatoid arthritis. Journal of Rheumatology 6: 584–593 (1979).
Cardoe, N. and Fowler, P.D.: Butacote: A six-year follow-up of patients with gastric intolerance to other medications. Journal of International Medical Research 5(Suppl. 2): 59–66 (1977).
Chalmers, A.; Offer, R. and Robinson, H.S.: A double-blind controlled study comparing the use of ASA and tolmetin with ASA and placebo in the treatment of rheumatoid arthritis. Current Therapeutic Research 24: 517–523 (1978).
Christensen, L.K.; Hansen, J.M. and Kristensen, M.: Sulphaphenazole-induced hypoglycaemic attacks in tolbutamide-treated diabetics. Lancet 2: 1298–1301 (1963).
Coe, F.L. and Kavalach, A.G.: Hypercalciuria and hyperuricosuria in patients with calcium nephrolithiasis. New England Journal of Medicine 291: 1344–1350 (1974).
Coe, R.O. and Bull, F.E.: Cirrhosis associated with methotrexate treatment of psoriasis. Journal of the American Medical Association 206: 1515–1520 (1968).
Cohen, A.S. and Calkins, E.: A controlled study of chloroquine as an anti-rheumatic agent. Arthritis and Rheumatism 1: 297–312 (1958).
Cohen, A. and Garber, H.E.: Comparison of choline magnesium trisilicylate and acetylsalicylic acid in relation to fecal blood loss. Current Therapeutic Research 23: 187–193 (1978).
Conn, H. and Blitzer, B.L.: Non-association of adrenocorticosteroid therapy and peptic ulcer. New England Journal of Medicine 294: 473–479 (1976).
Co-operating Clinics Committee of the American Rheumatism Association: A three month trial of indomethacin in rheumatoid arthritis with special reference to analysis and inference. Clinical Pharmacology and Therapeutics 8: 11–37 (1967).
Co-operating Clinics Committee of the American Rheumatism Association: A controlled trial of cyclophosphamide in rheumatoid arthritis. New England Journal of Medicine 283: 883–889 (1970).
Co-operating Clinics Committee of the American Rheumatism Association: A controlled trial of high dose and low dose cyclophosphamide in 82 patients with rheumatoid arthritis (abstract). Arthritis and Rheumatism 15: 434 (1972).
Croft, D.N.; Cuddigan, J.H.P. and Sweetland, C.: Gastric bleeding and benorylate, a new aspirin. British Medical Journal 3: 545–547 (1972).
Crouzet, J.; Camus, J.P. and Leca, A.P.: Lupus induit par la D-penicillamine au cours du traitement de la polyarthrite rhumatoide. Deux observations et étude immunologique de ce traitement. Annales de Medecine Interne 125: 71–79 (1974).
Currie, J.P.; Peebles-Brown, R.A. and Will, G.: Observations on the treatment of rheumatoid arthritis with butazolidin. Annals of the Rheumatic Diseases 12: 88–94 (1953).
Cuisinaud, G.; Legheand, J.; Leorca, G.; Belkahia, C; Lejeune, E. and Sassard, J.: Pharmacokinetics of fenbufen in man. European Journal of Clinical Pharmacology 16: 59–61 (1979).
Dall, J.L.C. and Keane, J.A.: Disturbances of pigmentation with chloroquine. British Medical Journal 1: 1387–1389 (1959).
Danowski, T.S.; Bonesai, J.V.; Sutton, R.D.; Webster, M.W. and Sarver, M.E.: Probabilities of pituitary-adrenal responsiveness after steroid therapy. Annals of Internal Medicine 61: 11–26 (1964).
Davies, D.S.: Phenylbutazone: Factors influencing plasma concentrations. Journal of International Medical Research 5(Suppl. 2): 15–19 (1977).
Dayton, P.G.; Sicam, L.E. and Landrau, M.: Metabolism of sulfinpyrazone (Anuturane) and other thio analogues of Phenylbutazone in man. Journal of Pharmacology and Experimental Therapeutics 132: 287–290 (1961).
Dayton, P.G.; Yu, T.F.; Chen, W.; Berger, L.; West, L.A. and Gutman, A.B.: The physiological disposition of probenecid, including renal clearance in man, studied by an improved method for its estimation in biological material. Journal of Pharmacology and Experimental Therapeutics 140: 278–286 (1963).
Desai, S.N.: Sudden gigantism of breasts: Drug induced?: British Journal of Plastic Surgery 26: 371–372 (1973).
De Schepper, P.J.; Tjandramaga, T.B.; Kram, P.R. and Getson, A.: Diflunisal (500mg bid): Effect upon gastrointestinal blood loss in man. Symposium on Diflunisal: New Perspectives in Analgesia, Abstract 18 (1978).
Dessain, P.; Estabrooks, T.F. and Gordon, A.J.: Piroxicam in the treatment of osteoarthrosis: A multicentre study in general practice involving 1218 patients. Journal of International Medical Research 7: 335–343 (1979).
Dick, W.C. and Buchanan, W.W.: Advances in the treatment of rheumatic disorders. Practitioner 207: 483–491 (1971).
Dixon, M.F.: Paracetamol hepatotoxicity. Lancet 1: 35 (1976).
Dixon, A. St. J.; Davies, J.; Dormandy, TL; Hamilton, EBD.; Holt, P.J.L.; Mason, R.M.; Thompson, M.; Weber, J.C.P. and Zutshi, D.W.: Synthetic D(-)penicillamine in rheumatoid arthritis. Double-blind controlled study of a high and low dosage regimen. Annals of the Rheumatic Diseases 34: 416–421 (1975).
Donadio, J.V.; Holley, K.E.; Ferguson, R.H. and Ilstrup, D.M.: Treatment of diffuse proliferative lupus nephritis with Prednisone and combined Prednisone and cylophosphamide. New England Journal of Medicine 299: 1151–1155 (1978).
Dorwart, B.B.; Gall, EP.; Schumacher, H.R. and Krauser, R.E.: Chrysotherapy in psoriatic arthritis. Arthritis and Rheumatism 21: 513–515 (1978).
Duncan, H.: Bone dynamics in rheumatoid arthritis patients treated with adrenal corticosteroids. Arthritis and Rheumatism 10: 216–227 (1967).
Dwosh, I.L.; Stein, H.B.; Urowitz, M.B.; Smythe, H.A.; Hunter, T. and Ogryzlo, M.A.: Azathioprine in early rheumatoid arthritis: Comparison with gold and chloroquine. Arthritis and Rheumatism 20: 685–692 (1977).
Editorial: Chloroquine myopathy. British Medical Journal 2: 605 (1971).
Editorial: Re-evaluation of parenteral pentazocine. Medical Letter on Drugs and Therapeutics 18: 46–47 (1976).
Edmar, D.: Effects of salicylates on the gastric mucosa as revealed by roentgen examination. Acta Radiologica (Diagnosis) 11: 57–64 (1971).
Ehrenbo, M.; Boreus, L.O. and Lonruth, U.: Bioavailability and first pass metabolism of oral pentazocine in man. Clinical Pharmacology and Therapeutics 22: 888–892 (1977).
Elion, G.B.; Kovensky, A.; Hitching, G.H.; Metz, E. and Rundles, R.W.: Metabolic studies of allopurinol, an inhibitor of xanthine oxidase. Biochemical Pharmacology 15: 863–880 (1966).
Elion, G.B.; Yu, T.F.; Gutman, A. and Hitchings, G.H.: Renal clearance of oxipurinol, the chief metabolite of allopurinol. American Journal of Medicine 45: 69–77 (1968).
Emmerson, B.T.: A comparison of uricosuric agents in gout, with special reference to eulphinpyrazone. Medical Journal of Australia 1: 839–844 (1963).
Emori, H.W.; Champion, G.D.; Bluestone, R. and Paulus, H.E.: Simultaneous pharmacokinetics of indomethacin in serum and synovial fluid. Annals of the Rheumatic Diseases 32: 433–435 (1973a).
Emori, H.W.; Paulus, H.E.; Bluestone, R. and Pearson, C.M.: The pharmacokinetics of indomethacin in serum (abstract). Clinical Pharmacology and Therapeutics 14: 134 (1973b).
Empire Rheumatism Council: Gold therapy in rheumatoid arthritis. Report of a multicentre controlled trial. Annals of the Rheumatic Diseases 19: 95–116 (1960).
Empire Rheumatism Council: Gold therapy in rheumatoid arthritis. Final report of a multicentre controlled trial. Annals of the Rheumatic Diseases 20: 315–333 (1961).
Erlich, G.E. and Roth, S.: Rheumatoid arthritis: Long-term therapy with tolmetin sodium. Orthopaedic Digest 4: 16–24 (1976).
Fauci, A.S.; Katz, P.; Haynes, B.F. and Wolff, S.M.: Cyclophosphamide therapy of severe systemic necrotizing vasculitis. New England Journal of Medicine 301: 235–238 (1979).
Feldges, D.H. and Barnes, C.G.: Treatment of psoriatic arthropathy with either azathioprine or methotrexate. Rheumatology and Rehabilitation 13: 120–124 (1974).
Feldman, D.; Funder, J.W. and Edelman, J.S.: Subcellular mechanisms in the action of adrenal steroids. American Journal of Medicine 53: 545–560 (1972).
Ferreira, M.L. and Buoniconti, A.: Trisomy after colchicine therapy. Lancet 2: 1304 (1968).
Findlay, J.W.A.; Butz, R.F. and Welch, R.M.: Codeine kinetics as determined by radioimmunoassay. Clinical Pharmacology and Therapeutics 22: 439–446 (1977).
Finkelstein, A.E.; Walz, D.T.; Batista, V.; Mizraji, M.; Roisman, F. and Misher, A.: Auranofin—New oral gold compound for treatment of rheumatoid arthritis. Annals of the Rheumatic Diseases 35: 251–257 (1976).
Fletcher, M.R.; Loebl, W. and Scott, J.T.: Feprazone, a new anti-inflammatory agent: Studies of potency and gastro-intestinal tolerance. Ann. Rheum. Dis. 34: 190–194 (1975).
Floman, Y.; Floman, U. and Zor, U.: Inhibition of Prostaglandin E release by anti-inflammatory steroids. Prostaglandins 11: 591–594 (1976).
Fowler, P.D.: Marrow toxicity of the pyrazoles. Annals of the Rheumatic Diseases 26: 344–345 (1967).
Fowler, P.D.: Voltarol: Diclofenac sodium. Clinics in Rheumatic Diseases 5: 427–464 (1979).
Fraser, T.N.: Gold treatment in rheumatoid arthritis. Annals of the Rheumatic Diseases 4: 71–75 (1945).
Freedman, A. and Bach, F.: Mepacrine and rheumatoid arthritis. Lancet 2: 321 (1952).
Freedman, A. and Steinberg, V.L.: Chloroquine in rheumatoid arthritis. A double blindfold trial of treatment for one year. Annals of the Rheumatic Diseases 19: 243–250 (1960).
Fremont-Smith, P. and Baglis, T.B.: Salicylate therapy in rheumatoid arthritis. Journal of the American Medical Association 192: 1133–1135 (1965).
Friedman, D.M. and Moore, M.E.: The efficacy of intra-articular corticosteroid for Osteoarthritis of the knee (abstract). Arthritis and Rheumatism 21: 556 (1978).
Furst, D.E.; Levine, S.; Srinivasan, R.; Metzger, A.L.; Bangert, R. and Paulus, H.E.: A double-blind trial of high versus conventional dosages of gold salts for rheumatoid arthritis. Arthritis and Rheumatism 20: 1473–1480 (1977).
Gallagher, J.C.; Aaron, J.; Horsman, A.; Wilkinson, R. and Nordin, B.E.C.: Corticosteroid osteoporosis. Clinics in Endocrinology and Metabolism 2: 355–368 (1973).
Gershwin, M.E.; Goetzl, E.J. and Steinberg, A.D.: Cyclophosphamide: Use in practice. Annals of Internal Medicine 80: 531–540 (1974).
Gibaldi, M. and Schwartz, M.A.: Apparent effect of probenecid on distribution of penicillin in man. Clinical Pharmacology and Therapeutics 9: 345–349 (1968).
Gibbons, R.B.: Complications of chrysotherapy. Archives of Internal Medicine 139: 343–346 (1979).
Gibbs, K. and Walshe, J.M.: Studies in 35S-label led DL-penicillamine in patients with Wilson’s Disease. Quarterly Journal of Medicine 40: 275–287 (1971).
Gibson, T.; Burry, H.C. and Ogg, C.: Goodpasture syndrome and D-penicillamine (corresp). Annals of Internal Medicine 84: 100 (1976).
Girdwood, R.H.: Death after taking medicaments. British Medical Journal 1: 501–504 (1974).
Glick, E.N.: Sulphinpyrazone in the treatment of arthritis associated with hyperuricaemia. Proceedings of the Royal Society of Medicine 54: 423–426 (1961).
Godfrey, R.G.; Calabro, J.J.; Mills, D. and Maltz, B.A.: A double-blind crossover trial of aspirin, indomethacin and Phenylbutazone in ankylosing Spondylitis (abstract). Arthritis and Rheumatism 15: 110 (1972).
Goldstein, G.: Mode of action of levamisole. Journal of the Rheumatic Diseases 5(Suppl. 4): 143–148 (1978).
Goodwin, C.S. and Sparell, G.: Inhibition of dapsone excretion by probenecid. Lancet 2: 884–885 (1969).
Gordon, B.L. and Yanagihara, R.: Treatment of systemic lupus erythematosus with the T-cell immunopotentiator levamisole: A follow-up report of 16 patients under treatment for a minimum of four months. Annals of Allergy 39: 227–236 (1977).
Graham, G.G.; Champion, G.D.; Day, R.O. and Pauli, P.D.: Patterns of plasma concentrations and urinary excretion of salicylates in rheumatoid arthritis. Clinical Pharmacology and Therapeutics 22: 410–420 (1977).
Greenberg, M.S. and Zambrano, S.S.: Aplastic agranulocytosis after allopurinol therapy. Arthritis and Rheumatism 15: 413–416 (1972).
Greene, M.L.; Fujimoto, W.Y. and Seegmiller, J.E.: Urinary xanthine stones—a rare complication of allopurinol therapy. New England Journal of Medicine 280: 426–427 (1969).
Grennan, D.M.; Ferry, D.G.; Ashworth, M.E.; Kenny, R.E. and MacKinnon, M.: The aspirin-ibuprofen interaction in rheumatoid arthritis. British Journal of Clinical Pharmacology 8: 497–503 (1979).
Gumpel, J.M.: Deaths associated with gold treatment: A reassessment. British Medical Journal 1: 215–216 (1978).
Gutman, A.B.: Treatment of primary gout: The present status. Arthritis and Rheumatism 8: 911–920 (1965).
Gutman, A.B. and Yu, T-F.: Protracted uricosuric therapy in tophaceous gout. Lancet 2: 1258–1260 (1957).
Hamilton, E.B.D. and Scott, J.T.: Hydroxychloroquine sulfate (‘Plaqueni‘) in treatment of rheumatoid arthritis. Arthritis and Rheumatism 5: 502–512 (1962).
Hardin, J.G.: Controlled study of the long-term effects of ‘total hand’ injection (abstract). Arthritis and Rheumatism 22: 619 (1979).
Harkness, A.J.L.; Burry, H.C. and Granarne, R.: A trial of feprazone in ankylosing Spondylitis. Rheumatology and Rehabilitation 16: 158–161 (1977).
Hart, F.D. and Boardman, P.L.: Indomethacin: A new non-steroidal anti-inflammatory agent. British Medical Journal 2: 965–970 (1963).
Hench, P.S.; Kendall, E.C.; Slocumb, C.H. and Polley, H.F.: The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocortisone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proceedings of the Staff Meeting of the Mayo Clinic 24: 181–197 (1949).
Hicks, R.M.; Hanson, V. and Kornreich, H.K.: The use of gold in the treatment of juvenile rheumatoid arthritis (abstract). Arthritis and Rheumatism 13: 323 (1970).
Hill, H.F.H.: Penicillamine in rheumatoid arthritis: Adverse effects. Scandinavian Journal of Rheumatology Supplement 28: 94–99 (1979).
Hill, H.F.H.; Hill, A.G.S.; Day, AT.; Brown, R.M.; Golding, J.R. and Lyle, W.H.: Maintenance dose of penicillamine in rheumatoid arthritis: a comparison between the standard and a response-related flexible regimen. Annals of the Rheumatic Diseases 38: 429–433 (1979).
Hobbs, D.C. and Twomey, T.M.: Piroxicam pharmacokinetics in man: Aspirin and antacid studies. Journal of Clinical Pharmacology 19: 270–281 (1979).
Hollander, J.L.; Jessar, R.A. and Brown, E.M.: Intra-synovial corticosteroid therapy: A decade of use. Bulletin on Rheumatic Diseases 11: 239–240 (1961a).
Hollander, J.L.; Jessar, R.A.; Restifo, R.A. and Fort, H.J.: A new intra-articular steroid ester with longer effectiveness (abstract). Arthritis and Rheumatism 4: 422 (1961b).
Holt, P.J.L. and Hawkins, C.F.: Indomethacin: Studies of absorption and the use of suppositories. British Medical Journal 1: 1354–1356 (1965).
Hunder, G.G.; Sheps, S.G.; Allen, G.L. and Joyce, J.W.: Daily and alternate day corticosteroid regimens in treatment of giant cell arteritis: Comparison in a prospective study. Annals of Internal Medicine 82: 613–618 (1975).
Hunter, T.; Urowitz, M.B.; Duncan, D.A.; Smythe, H.A. and Ogryzlo, M.A.: Azathioprine in rheumatoid arthritis: A long-term follow-up study. Arthritis and Rheumatism 18: 15–20 (1975).
Huskisson, E.C.: Simple analgesics for arthritis. British Medical Journal 4: 196–200 (1974).
Huskisson, E.C.: Anti-inflammatory drugs. Seminars in Arthritis and Rheumatism 7: 1–20 (1977).
Huskisson, E.C.: Routine drug treatment of rheumatoid arthritis and other rheumatic diseases. Clinics in Rheumatic Diseases 5: 697–706 (1979).
Huskisson, E.C. and Scott, J.: Sulindac. Trials of a new anti-inflammatory drug. Annals of the Rheumatic Diseases 37: 89–92 (1978).
Huskisson, E.C.; Taylor, R.T.; Burston, D.; Chuter, P.J. and Hart, F.D.: Evening indomethacin in the treatment of rheumatoid arthritis. Annals of the Rheumatic Diseases 29: 393–396 (1970).
Huskisson, E.C.; Woolf, D.L.; Balme, H.W.; Scott, J. and Franklyn, S.: Four new anti-inflammatory drugs: Responses and variations. British Medical Journal 1: 1048–1049 (1976).
Inman, W.H.W.: Study of fatal bone marrow suppression with special reference to Phenylbutazone and oxyphenbutazone. British Medical Journal 1: 1500–1505 (1977).
Irby, R.; Toone, E. and Owen, D.: Bone marrow depression associated with allopurinol therapy (abstract). Arthritis and Rheumatism 9: 860 (1966).
Jaffe, I.A.: Rheumatoid arthritis with arteritis. Report of a case treated with penicillamine. Annals of Internal Medicine 61: 556–563 (1964).
Jaffe, I.A.: D-penicillamine. Bulletin on the Rheumatic Diseases 28: 948–952 (1978).
Jarzobski, J.; Ferry, J.; Wombolt, D.; Fitch, D.M. and Egan, J.D.: Vasculitis with allopurinol therapy. American Heart Journal 79: 116–121 (1970).
Joint Committee of the Medical Research Council and Nuffield Foundation: A comparison of prednisolone with aspirin or other analgesics in the treatment of rheumatoid arthritis. Annals of the Rheumatic Diseases 18: 173–187 (1959).
Joint Committee of the Medical Research Council and Nuffield Foundation: A comparison of prednisolone with aspirin or other analgesics in the treatment of rheumatoid arthritis. Annals of the Rheumatic Diseases 19: 331–337 (1960).
Kaiser, D.G. and Glenn, E.M.: Aspirin-flurbiprofen interaction in the adjuvant-induced polyarthritic rat. Research Communications in Chemical Pathology and Pharmacology 9: 583–586 (1979).
Kantor, T.G.: Ibuprofen. Annals of Internal Medicine 91: 877–882 (1979).
Kantrowitz, F.; Robinson, D.R.; McGuire, M.B. and Levine, L.: Corticosteroids inhibit Prostaglandin synthesis in rheumatoid synovia. Nature 258: 737–739 (1975).
Kay, A.G.L.: Myelotoxicity of gold. British Medical Journal 1: 1266–1268 (1976).
Kay, A.G.L.: Myelotoxicity of D-penicillamine. Annals of the Rheumatic Diseases 38: 232–236 (1979).
Kean, W.F. and Anastassiades, T.P.: Long-term chrysotherapy: Incidence of toxicity and efficacy during sequential time periods. Arthritis and Rheumatism 22: 495–501 (1979).
Kean, W.F.; Dwosh, I.L.; Anastassiades, T.P.; Ford, P.M. and Kelly, H.G.: The toxicity pattern of D-penicillamine therapy. A guide to its use in rheumatoid arthritis. Arthritis and Rheumatism 23: 158–164 (1980).
Kenwright, S. and Levi, A.J.: Impairment of hepatic uptake of rifamycin antibiotics by probenecid, and its therapeutic implications. Lancet 2: 1401–1405 (1973).
Kersley, G.D.: Amethopterin (methotrexate) in connective tissue disease—psoriasis and polyarthritis. Annals of the Rheumatic Diseases 27: 64–66 (1968).
Kincaid-Smith, P.: Analgesic nephropathy. Kidney International 13: 1–4 (1978).
Klein, J.M. and Finland, O.: Ampicillin activity in vitro and absorption and excretion in normal young men. American Journal of the Medical Sciences 246: 10–26 (1963).
Klein, R.G.; Arnaud, S.B.; Gallagher, J.C.; DeLuca, J.F. and Riggs, B.L.: Intestinal calcium absorption in exogenous hypercortisonism—role of 25-hydroxyvitamin D and corticosteroid dose. Journal of Clinical Investigation 60: 253–259 (1977).
Klinefelter, H.F.: Re-institution of gold therapy in rheumatoid arthritis after mucocutaneous reactions. Journal of Rheumatology 2: 21–27 (1975).
Klinenberg, J.R. and Miller, R.: Effect of corticosteroids on blood salicylate concentration. Journal of the American Medical Association 194: 601–604 (1965).
Kwan, K.C.; Breault, G.O.; Umbenhauer, E.R.; McMahon, F.G. and Duggan, D.E.: Kinetics of indomethacin absorption, elimination, and enterohepatic circulation in man. Journal of Pharmacokinetics and Biopharmaceutics 4: 255–280 (1976).
Kwan, K.C.; Duggan, D.E.; Van Arman, E.G. and Shen, T.Y.: Sulindac: chemistry, pharmacology and pharmacokinetics. European Journal of Rheumatology and Inflammation 1: 9–11 (1978).
Lawrence, J.S.: Comparative toxicity of gold preparations in treatment of rheumatoid arthritis. Annals of Rheumatic Diseases 35: 171–173 (1976).
Lee, P.; Anderson, J.A.; Miller, J.; Webb, J. and Buchanan, W.W.: Evaluation of analgesic action and efficacy of anti-rheumatic drugs. Study of 10 drugs in 684 patients with rheumatoid arthritis. Journal of Rheumatology 3: 283–294 (1976).
Leonards, JR.: Absence of gastrointestinal bleeding following administration of salicylsalicylic acid. Journal of Laboratory and Clinical Medicine 74: 911–914 (1969).
Levin, H.M.; Bare, W.W. and Berry, F.N.: Acetaminophen with codeine for the relief of severe pain in post-partum patients. Current Therapeutic Research 16: 921–927 (1973).
Levy, G.; Tsuchiya, T. and Amsel, L.P.: Limited capacity for salicylphenolic glucuronide formation and its effects on the kinetics of salicylate elimination in man. Clinical Pharmacology and Therapeutics 13: 258–268 (1972).
Lewis, G.P.; Jusko, W.J.; Burke, C.W. and Graves, L.: Prednisone side effects and serum protein levels. Lancet 2: 778–780 (1971).
Lidsky, M.D.; Stuart, J.T. and Billings, S.: A double-blind study of cyclophosphamide in rheumatoid arthritis. Arthritis and Rheumatism 16: 148–153 (1973).
Liebling, M.R.; Altman, R.D.; Benedek, T.G.; Bennaham, D.A.; Blaschke, J.A.; Bower, R.J.; Calabro, J.J.; Caldwell, J.R.; Collins, R.L.; Felt, J.; Hamaty, D.; Jimeno, C.V.; Umbenhauer, E.R. and Wilkens, R.F.: A double-blind, multiclinic trial of sulindac (MK-231) in the treatment of ankylosing Spondylitis (abstract). Arthritis and Rheumatism 18: 411 (1975).
Liegler, D.; Henderson, E.; Hahn, M.A. and Oliverio, V.: Renal clearance and in vivo protein binding of methotrexate in man and changes with salicylate administration (abstract). Proceedings of the American Association of Cancer Research 8: 41 (1967).
Livanou, T.; Ferriman, D. and James, V.H.T.: Recovery of hypothalmic-pituitary-adrenal axis function after corticosteroid therapy. Lancet 2: 856–859 (1967).
Loan, W.B. and Morrison, J.D.: Strong analgesics: Pharmacological and therapeutic aspects. Drugs 5: 108–143 (1973).
Luukkainen, R.; Isomaki, H. and Kajander, A.: Effect of gold treatment on the progression of erosions in RA patients. Scandinavian Journal of Rheumatology 6: 123–127 (1977).
MacKercher, P.A.; Ivey, K.J.; Baskin, W.N. and Krause, W.J.: Protective effect of Cimetidine on aspirin-induced gastric mucosal damage. Annals of Internal Medicine 87: 676–679 (1977).
Mainland, D. and Sutcliffe, M.I.: Hydroxychloroquine sulfate in rheumatoid arthritis, a six month double-blind trial. Bulletin on the Rheumatic Diseases 13: 287–290 (1962).
Malaviya, A.N.; Many, A. and Schwartz, R.S.: Treatment of dermatomyositis with methotrexate. Lancet 2: 485–488 (1968).
Malawista, S.E.: Colchicine: A common mechanism for its anti-inflammatory and anti-mitotic effects. Arthritis and Rheumatism 11: 191–197 (1968).
Manz, G. and Franke, M.: The treatment of ankylosing Spondylitis with TolectinR and indomethacin respectively: A randomized double-blind study. Therapiewoche 27: 2288–2297 (1977).
Marbet, G.A.; Duckert, F.-, Walter, M.; Six, P. and Airenne, H.: Interaction study between phenprocoumon and flurbiprofen. Current Medical Research and Opinion 5: 26–31 (1977).
Martin, J.H.; Gordon, M. and Wallace, R.: Methotrexate in psoriasis. Archives of Dermatology 96: 431–433 (1967).
Mascarhenas, B.R.; Granda, J.L. and Freyberg, R.H.: Gold metabolism in patients with rheumatoid arthritis treated with gold compounds — re-investigated. Arthritis and Rheumatism 15: 391–402 (1972).
Mason, M.; Currey, H.L.F.; Barnes, C.G.; Dunne, J.F.; Hazleman, B.L. and Strickland, I.D.: Azathioprine in rheumatoid arthritis. British Medical Journal 1: 420–422 (1969).
McCarty, D.J.: Treatment of rheumatoid joint inflammation with triamcinolone hexacetonide. Arthritis and Rheumatism 15: 157–173 (1972).
McCarty, D.J. and Hogan, J.M.: Inflammatory reaction after intrasynovial injection of microcrystalline adrenocorticosteroid esters. Arthritis and Rheumatism 7: 359–367 (1964).
McChesney, E.W.; Fasco, M.J. and Banks, W.F.: The metabolism of chloroquine in man during and after repeated oral dosage. Journal of Pharmacology and Experimental Therapeutics 158: 323–331 (1967).
McGiff, J.C.; Crowshaw, K.; Terraguo, N.A.; Lonigro, A.J.; Strand, J.C.; Williamson, M.A.; Lee, J.B. and Ng, K.K.F.: Prostaglandin-like substances appearing in canine renal venous blood during renal ischemia. Circulation Research 27: 765–782 (1970).
Merlin, H.E.: Azoospermia caused by colchicine. Fertility and Sterility 23: 180–181 (1972).
Metzger, A.L.; Bohan, A.; Goldberg, L.S.; Bluestone, R. and Pearson, CM.: Polymyositis and dermatomyositis: Combined methotrexate and corticosteroid therapy. Annals of Internal Medicine 81: 182–189 (1974).
Meyers, O.L.; Quantock, O.P.; Joubert, P.G.; Du, P.; Louw, D.F.; Marais, D.F.; McDonald Scott, W.A. and Müller, F.O.: A multicentre trial of Voltaren in the treatment of rheumatoid arthritis. South African Medical Journal 48: 2013–2017 (1974).
Mielants, H. and Veys, EM.: A study of the hematological side-effects of levamisole in rheumatoid arthritis with recommendations. Journal of the Rheumatic Diseases 5(Suppl. 4): 77–83 (1978).
Miller, R.R.: Propoxyphene: A review. American Journal of Hospital Pharmacy 34: 413–423 (1977).
Millingen, K.S. and Suerth, E.: Peripheral neuromyopathy following chloroquine therapy. Medical Journal of Australia 1: 840–841 (1966).
Mjolnerod, O.K.; Rasmussen, K.; Dommerud, S.A. and Gjeruldsen, ST.: Congenital connective-tissue defect probably due to D-penicillamine treatment in pregnancy. Lancet 1: 673–675 (1971).
Moncada, S. and Vane, JR.: Mode of action of aspirin-like drugs. Advances in Internal Medicine 24: 1–22 (1979).
Muller, F.O.; Hundt, H.K.L. and de Kock, A.C.: Decreased steady-state salicylic acid plasma levels associated with chronic aspirin ingestion. Current Medical Research and Opinion 3: 417–422 (1975).
Multicentre Study Group: Levamisole in rheumatoid arthritis: a multicentre randomized double-blind study comparing two dosage schedules of levamisole and placebo. Lancet 2: 1007–1012 (1978a).
Multicentre Study Group: A multicentre randomized double-blind study comparing two dosages of levamisole in rheumatoid arthritis. Journal of the Rheumatic Diseases 5(Suppl. 4): 5–10 (1978b).
Multicentre Trial Group: Controlled trial of D(-)penicillamine in severe rheumatoid arthritis. Lancet 1: 275–280 (1973).
Munthe, E.; Jellum, E. and Anseth, J.: Some aspects of the mechanism of action of penicillamine in rheumatoid arthritis. Scandinavian Journal of Rheumatology Supplement 28: 6–12 (1979).
Murthy, M.H.V.; Rhymer, A.R. and Wright, V.: tIndomethacin or prednisolone at night in rheumatoid arthritis? Rheumatology and Rehabilitation 17: 8–13 (1978).
Neild, G.H.; Gartner, H.V. and Bohle, A.: Penicillamine induced membranous glomerulonephritis. Scandinavian Journal of Rheumatology Supplement 28: 79–90 (1979).
Nemati, M.; Kyle, M.C. and Fries, E.D.: Clinical study of ticrynafen: a new diuretic, antihypertensive, and uricosuric agent. Journal of the American Medical Association 237: 652–657 (1977).
Nevins, M.; Berque, S.; Corwin, N. and Lyon, L.: Phenylbutazone and pulmonary edema (corresp). Lancet 2: 1358 (1969).
Nuki, G.; Downie, W.W.; Dick, W.C, Whaley, K.; Spooner, JB.; Darby-Dowman, M.A. and Buchanan, W.W.: Clinical trial of pentazocine in rheumatoid arthritis — observations on the value of potent analgesics and placebos. Annals of the Rheumatic Diseases 32: 436–443 (1973).
Nylander, U.: Ocular damage in chloroquine therapy. Acta Ophthalmologica 44: 335–348 (1966).
O’Rourke, R.A. and Eckert, G.E.: Methotrexate-induced hepatic injury in an adult. Archives of Internal Medicine 113: 191–194 (1964).
Patzschke, K.; Wegner, L.; Kaller, H. and Horster, F.A.: Pharkokinetische Untersuchungen nach oraler applikation von radioactiv markierten D-penicillamin an probanden. Zeitschrift fur Rheumatologie 36: 96–105 (1977).
Paulus, H.E.; Siegel, M.; Mongan, E.; Okun, R. and Calabro, J.J.: Variations of serum concentrations and life of salicylate in patients with rheumatoid arthritis. Arthritis and Rheumatism 14: 527–532 (1971).
Penner, J.A. and Abbrecht, P.H.: Lack of interaction between ibuprofen and warfarin. Current Therapeutic Research 18: 862–871 (1975).
Penneys, N.S.; Ackerman, A.B. and Gottlieb, N.L.: Gold dermatitis: A clinical and histopathological study. Archives of Dermatology 109: 372–376 (1974).
Percy, J.S.; Stephenson, P. and Thompson, M.: Indomethacin in the treatment of rheumatic diseases. Annals of the Rheumatic Diseases 23: 226–231 (1964).
Perel, J.M.; Dayton, P.G.; Snell, M.M.; Yu, T-F. and Gutman, A.B.: Studies of interactions among drugs in man at the renal level. Probenecid and sulphinpyrazone. Clinical Pharmacology and Therapeutics 10: 834–840 (1969).
Persellin, R.H. and Schmid, F.R.: The use of sulphinpyrazone in the treatment of gout reduces serum uric acid levels and diminishes severity of arthritic attacks, with freedom from significant toxicity. Journal of the American Medical Association 175: 971–975 (1961).
Plotz, P.H.; Klippel, J.H.; Decker, J.L.; Grauman, D.; Wolff, B.; Brown, B.C. and Rutt, G.: Bladder complications in patients receiving cyclophosphamide for systemic lupus erythematosus or rheumatoid arthritis. Annals of Internal Medicine 91: 221–223 (1979).
Popert, A.J.; Meyers, K.A.E.; Sharp, J. and Bier, F.: Chloroquine diphosphate in rheumatoid arthritis. Annals of the Rheumatic Diseases 20: 18–35 (1961).
Radi, I.; Matoso, L.; Posmantir, A. and Papalexiou, P.: Safety and efficacy of Piroxicam in the treatment of ankylosing Spondylitis. European Journal of Rheumatology and Inflammation 1: 349–351 (1978).
Reeback, J.S.; Chakraborty, J.; English, J.; Gibson, T. and Marks, V.: Plasma steroid levels after intra-articular injection of prednisolone acetate in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 39: 22–24 (1980).
Rheinberger, K.: Efficacy and tolerance of Voltaren and indomethacin in patients with ankylosing Spondylitis. Therapiewoche 26: 2916–2920 (1976).
Rhymer, A.H.: Sulindac. Clinics in Rheumatic Diseases 5: 553–568 (1979).
Ridolfo, A.S.; Nickander, R. and Mikulaschek, W.M.: Fenoprofen and benoxaprofen. Clinics in Rheumatic Diseases 5: 393–410 (1979).
Robertson, C.E.; Ford, M.J.; Van Someren, V.; Dlugolecka, M. and Prescott, L.F.: Mefenamic acid nephropathy. Lancet 2: 232–233 (1980).
Rosenthal, M.: A critical review of the effect of levamisole in rheumatic diseases other than rheumatoid arthritis. Journal of the Rheumatic Diseases 5(Suppl. 4): 97–100 (1978).
Rothermich, N.O.; Philips, U.K.; Bergen, W. and Thomas, M.H.: Chrysotherapy: A prospective study. Arthritis and Rheumatism 19: 1321–1327 (1976).
Rubin, A.; Rodda, B.E.; Warrick, P.; Graber, C.M. and Ridolfo, A.S.: Interactions of aspirin with non-steroidal anti-inflammatory drugs in man. Arthritis arid Rheumatism 16: 635–645 (1973).
Rudnicki, R.D.; Gresham, G.E. and Rothfield, N.F.: The efficacy of antimalarials in systemic lupus erythematosus. Journal of Rheumatology 2: 323–330 (1975).
Rundles, R.W.; Metz, E.N. and Silberman, H.R.: Allopurinol in the treatment of gout. Annals of Internal Medicine 64: 229–258 (1966).
Ryan, J.R.; Jain, A.K.; McMahon, F.G. and Vargas, R.: On the question of interaction between sulindac and tolbutamide in the control of diabetes. Clinical Pharmacology and Therapeutics 21: 231–233 (1977).
Rynes, R.I.; Krohel, G.; Falbo, A.; Reinecke, R.D.; Wolfe, B. and Bartholomew, L.E.: Ophthalmologic safety of long-term hydroxychloroquine therapy. Arthritis and Rheumatism 22: 832–836 (1979).
Samter, M.: The acetyl in aspirin. Annals of Internal Medicine 71: 208–209 (1969).
Samter, M. and Beers, R.T.: Intolerance to aspirin: Clinical studies and consideration of its pathogenesis. Annals of Internal Medicine 68: 975–983 (1968).
Sanchez, G.: Enhancement of heparin effect by probenecid. New England Journal of Medicine 292: 48 (letter) (1975).
Sandvig, K.: Chloroquine (Resochin) effects on the cornea. Acta Ophthalmologica 44: 355–360 (1966).
Schacter, D. and Manis, J.G.: Salicylate and salicyl conjugates: Fluorimetric estimation, biosynthesis, and renal excretion in man. Journal of Clinical Investigation 37: 800–807 (1958).
Senary, W.L.; Lewis, R.J. and Rowland, L.: Warfarin-phenylbutazone interaction in man; a long-term multiple dose study. Research Communications in Chemical Pathology and Pharmacology 10: 663–668 (1975).
Schein, P.S. and Winokur, J.H.: Immunosuppressive and cytotoxic therapy: long-term complications. Annals of Internal Medicine 82: 84–95 (1975).
Schraeder, P.L.; Peters, H.A. and Dahl, D.S.: Polymyositis and penicillamine. Archives of Neurology 27: 456–457 (1972).
Schuermans, Y.: Levamisole in rheumatoid arthritis. Lancet 1: 111 (1975).
Segre, E.J.: Naproxen. Clinics in Rheumatic Diseases 5: 411–426 (1979).
Segre, E.J.; Chaplin, M.; Forchielli, E.; Runkel, R. and Sevelius, H.: Naproxen-aspirin interactions in man. Clinical jpharmacology and Therapeutics 15: 374–379 (1974).
Seidenfeld, A.M.; Smythe, H.A.; Ogryelo, M.A., Urowitz, M.B. and Dotten, D.A.: Acute leukemia in rheumatoid arthritis treated with cytotoxic agents. Journal of Rheumatology 3: 295–304 (1976).
Self, T.H.; Evans, W.E. and Ferguson, T.: Drug enhancement of warfarin activity. Lancet 2: 557–558 (1975).
Shapiro, H.A.; Trowbridge, J.O.; Lee, J.C. and Maibach, H.I.: Liver disease in psoriatics — an effect of methotrexate therapy? Archives of Dermatology 110: 547–551 (1974).
Sharp, J.T.; Lidky, M.D.; Duffy, J.; Thompson, H.K.; Person, B.D.; Masri, A.F. and Andrianakos, A.A.: Comparison of two dosage schedules of gold salts in the treatment of rheumatoid arthritis: relationship of serum gold levels to terapeutic response. Arthritis and Rheumatism 20: 1179–1187 (1977).
Shearer, R.V. and Dubois, E.L.: Ocular changes induced by long-term hydroxychloroquine therapy. American Journal of Ophthalmology 64: 245–252 (1967).
Sigler, J.W.; Bluhm, G.B.; Duncan, H.; Sharp, J.T.; Ensign, D.C. and McCrum, W.R.: Gold salts in the treatment of rheumatoid arthritis: a double-blind study. Annals of Internal Medicine 80: 21–26 (1974).
Silverberg, D.S.; Kidd, E.G. and Shnitka, T.K.: Gold nephropathy: A clinical and pathological study. Arthritis and Rheumatism 13: 812–825 (1970).
Silvergleid, A.J. and Schier, S.L.: Acute myelogenous leukemia in two patients treated with azathioprine for non-malignant disease. American Journal of Medicine 57: 885–888 (1974).
Silvoso, G.R.; Ivey, K.J., Butt, J.H.; Lockard, O.O.; Holt, S.D.; Sisk, C.; Baskin, W.N.; MacKercher, P.A. and Hewett, J.: Incidence of gastric lesions in patients with rheumatic disease on chronic aspirin therapy. Annals of Internal Medicine 91: 517–520 (1979).
Skeith, M.D.; Simkin, P.A. and Healey, L.A.: Renal excretion of indomethacin and its inhibition by probenecid. Clinical Pharmacology and Therapeutics 9: 89–93 (1968).
Sladek, N.E.: Therapeutic efficacy of cylophosphamide as a function of its metabolism. Cancer Research 32: 535–542 (1972).
Smythe, C.J. and Percy, J.S.: Comparison of Phenylbutazone and indomethacin in acute gout. Annals of the Rheumatic Diseases 32: 351–353 (1973).
Smythe, H.A.; Ogryzlo, M.A.; Murphy, E.A. and Mustard, J.F.: The effect of sulphinpyrazone (Anturan) on platelet economy and blood coagulation in man. Canadian Medical Association Journal 92: 818–821 (1965).
Sokoloff, M.C.; Goldberg, L.S. and Pearson, C.M.: Treatment of corticosteroid-resistant Polymyositis with methotrexate. Lancet 1: 14–16 (1971).
Solomon, L. and Abrams, G.: Voltaren in the treatment of rheumatoid arthritis. South African Medical Journal 48: 949–952 (1974).
Spector, S.L.; Morris, H.G. and Seiner, J.C.: Pulmonary, Prostaglandin and clinical response of asthmatic patients with aspirin idiosyncracy to a new nonsteroidal anti-inflammatory substance compared to aspirin (abstract). Journal of Allergy and Clinical Immunology 63: 154–155 (1979).
Standel, W.: The question of the drug treatment of ankylosing Spondylitis. Therapiewoche 27: 2273–2287 (1977).
Staszewska-Barczak, J. and Vane, J.R.: The role of Prostaglandins in the local control of circulation. Clinical and Experimental Pharmacology and Physiology 2 (Suppl.): 71–78 (1975).
Steigerwald, J.C.: Piroxicam and rheumatoid arthritis: A double-blind 16-week study comparing Piroxicam and indomethacin. European Journal of Rheumatology and Inflammation 1: 360–364 (1978).
Stein, H.B.; Patterson, A.C.; Offer, R.C.; Atkins, C.J.; Teufel, A. and Robinson, H.S.: Adverse effects of D-penicillamine in rheumatoid arthritis. Annals of Internal Medicine 92: 24–29 (1980).
Stephens, W.H.; El-Ghobarey, A.F.; MacLeod, M.M. and Buchanan, W.W.: A double-blind, crossover trial of mefenamic acid, sulindac and flurbiprofen in rheumatoid arthritis. Curr. Med. Res. Opin. 5: 754–758 (1979).
Stevenson, D.D.; Arroyave, C.M.; Bhat, K.N. and Tan, E.M.: Oral aspirin challenges in asthmatic patients: A study of plasma histamine. Clinical Allergy 6: 493–505 (1976).
Stockman, A.; Richter, D.; Barraclough, D.; Muirden, K.D.; Macdonald, I. and Kincaid-Smith, P.: Difficulties in the use of D-penicillamine in the treatment of rheumatoid arthritis. Australia and New Zealand Journal of Medicine 9: 495–503 (1979).
Stone, E.: An account of the success of the bark of the willow in the cure of agues. Philosophical Society Transactions 53: 195–200 (1763).
Straitigos, J.D.; Bartsokas, S.K. and Capetanakis, J.: Further experiences with toxic epidermal necrolysis incriminating allopurinol, pyrazolone and derivatives. British Journal of Dermatology 86: 564–567 (1972).
Sweetman, R.: Corticosteroid arthropathy and tendon rupture. Journal of Bone and Joint Surgery 51B: 397–398 (1969).
Symoens, J. and Rosenthal, M.: Levamisole in the modulation of the immune response: The current experimental and clinical state. Journal of the Reticuloendothelial Society 21: 175–221 (1977).
Szczeklik, A.; Gryglewski, R.J. and Czeniawska-Mysik, G.: Relationship of inhibition of Prostaglandin synthesis by analgesics to asthma attacks in aspirin sensitive patients. British Medical Journal 1: 67–69 (1975).
Szczeklik, A.; Gryglewski, R.J.; Czeniawska-Mysik, G. and Zmuda, A.: Aspirin induced asthma. Journal of Allergy and Clinical Immunology 58: 10–18 (1976).
Talbott, J.H.: Drug treatment of gout. Clinics in Rheumatic Diseases 5: 657–672 (1979).
Tausch, G. and Eberl, R.: Efficacy, tolerance and safety of piroxicam in the treatment of acute gout. European Journal of Rheumatology and Inflammation 1: 365–368 (1978).
Telhag, H.: Safety and efficacy of Piroxicam in the treatment of osteoarthrosis. European Journal of Rheumatology and Inflammation 1: 352–355 (1978).
Tjandramaga, T.B.; Cucinell, S.A. and Israeli, Z.H.: Observations on the disposition of probenecid in patients receiving allopurinol. Pharmacology 8: 259–272 (1972).
Tolman, E.L. and Partridge, P.: Multiple sites of interaction between Prostaglandins and non-steroidal anti-inflammatory agents. Prostaglandins 9: 349–359 (1975).
Tornroth, T. and Skrifvars, B.: Gold nephropathy prototype of membranous glomerulonephritis. American Journal of Pathology 75: 573–584 (1974).
Townes, A.S.; Sowa, J.M. and Shulman, L.E.: Controlled trial of cyclophosphamide in rheumatoid arthritis: An 18 month double-blind crossover study. Arthritis and Rheumatism 15: 129–130 (Abstract) (1972).
Urowitz, M.B.; Hunter, T. and Bookman, A.A.: Azathioprine in rheumatoid arthritis: a double-blind study comparing full dose to half dose. Journal of Rheumatology 1: 274–281 (1974).
Vane, JR.: Inhibition of Prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature (New Biology) 231: 232–235 (1971).
Van Gerwen, F.; Van DerKoist, J.K. and Gribnau, F.W.J.: Double-blind trial of naproxen and Phenylbutazone in ankylosing Spondylitis. Annals of the Rheumatic Diseases 37: 85–88 (1978).
Vesell, E.S.; Passananti, G.T. and Greene, F.E.: Impairment of drug metabolism in man by allopurinol and nortriptyline. New England Journal of Medicine 283: 1484–1488 (1970).
Vesell, E.S.; Passananti, G.T. and Johnson, A.O.: Failure of indomethacin and warfarin to interact in normal human volunteers. Journal of Clinical Pharmacology 15: 486–495 (1975).
Veys, E.M. and Mielants, H.: Experience and recommendations for treatment schedule of levamisole in rheumatoid arthritis. Journal of the Rheumatic Diseases 5(Suppl. 4): 31–41 (1978).
Voipio, H.: Incidence of chloroquine retinopathy. Acta Ophthalmologica 44: 349–354 (1966).
Wallace, S.L.: Colchicine and new anti-inflammatory drugs for the treatment of acute gout. Arthritis and Rheumatism 18: 847–851 (1975).
Wallace, S.L.; Bernstein, D. and Diamond, H.: Diagnostic value of the colchicine therapeutic trial. Journal of the American Medical Association 199: 525–528 (1967).
Wallace, S.L. and Ertel, N.H.: Occupancy approach to colchicine dosage. Lancet 2: 1250–1251 (1970).
Walton, J.; Watson, B.S. and Ney, R.L.: Alternate-day vs. shorter interval steroid administration. Archives of Internal Medicine 126: 601–607 (1970).
Weinberger, M.: Analgesic sensitivity in children with asthma. Pediatrics 62: (Suppl.): 910–916 (1978).
Whitsett, T.L.; Barry, J.P.; Czerwinski, A.W.; Hall, W.H. and Hampton, J.W.: Tolmetin and warfarin: a clinical investigation to determine if interaction exists, in Tolmetin, A New Non-Steroidal Anti-Inflammatory Agent, pp.134–141 (Excerpta Medica, Princeton 1975).
Wilkens, R.F. and Segre, E.J.: Combination therapy with naproxen and aspirin in rheumatoid arthritis. Arthritis and Rheumatism 19: 677–682 (1976).
Winder, C.V.; Kaump, D.H.; Glazko, A.J. and Holmes, E.L.: Pharmacology of the fenamates. Annals of Physical Medicine Supplement: 7-49 (1966).
Winter, C.A.; Risely, E.A. and Nuss, G.W.: Anti-inflammatory and anti-pyretic activities of indomethacin, 1-(p-chlorobenzyl) 5-methoxy-2-methylindole-3-acetic acid. Journal of Pharmacology and Experimental Therapeutics 141: 369–376 (1963).
Wolff, S.M.; Fauci, A.S.; Horn, R.G. and Dale, D.C.: Wegener’s Granulomatosis. Annals of Internal Medicine 81: 513–525 (1974).
Wyngaarden, J.B. and Kelley, W.N.: Gout and Hyperuricemia, pp.484–485 (Grune and Stratton, New York 1976).
Yu, T.-F.; Burns, J.J. and Gutman, A.B.: Results of a clinical trial of G-28315, a sulfoxide analogue of Phenylbutazone, as a uricosuric agent in gouty subjects. Arthritis and Rheumatism 1: 532–543 (1958).
Yu, T.-F.; Dayton, P.G. and Gutman, A.B.: Mutual suppression of the uricosuric effects of sulphinpyrazone and salicylate: A study in interactions between drugs. Journal of Clinical Investigation 42: 1330–1339 (1963).
Yu, T.-F. and Gutman, A.B.: Efficacy of colchicine prophylaxis in gout. Annals of Internal Medicine 55: 179–191 (1961).
Zvaifler, N.J. and Rubin, M.: The metabolism of chloroquine. Arthritis and Rheumatism 5: 330 (Abstract) (1962).
Zvaifler, N.J.; Rubin, M. and Bernstein, H.: Chloroquine metabolism — drug excretion and tissue deposition (abstract). Arthritis and Rheumatism 6: 799–800 (1963).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Craig, G.L., Buchanan, W.W. Antirheumatic Drugs: Clinical Pharmacology and Therapeutic Use. Drugs 20, 453–484 (1980). https://doi.org/10.2165/00003495-198020060-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198020060-00002